Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection a clinical trial

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 4, 2013, Pages 439-445

  Adetifa, Ifedayo M ^a   Ota, Martin O C ^a   Jeffries, David J ^a   Lugos, Moses D ^a   Hammond, Abdulrahman S ^a   Battersby, Nicholas J ^a   Owiafe, Patrick K ^a   Donkor, Simon D ^a   Antonio, Martin ^a   Ibanga, Hannah B ^a   Brookes, Roger H ^a   Aka, Peter ^a   Walton, Robert ^a   Adegbola, Richard A ^a   Hill, Philip C ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Clinical trial; ELISPOT reversion; IFN g release assays; Isoniazid; Latent tuberculosis infection

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; ISONIAZID; PLACEBO;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GAMMA INTERFERON ELISA; GENOTYPE; HUMAN; HUMAN TISSUE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINALYSIS;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GAMBIA; HUMANS; INTERFERON-GAMMA; ISONIAZID; LATENT TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873949822     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201208-1352OC     Document Type: Article

References (40)

1. World Health Organization. Global tuberculosis control: WHO report 2011 [accessed 2012 September 20]. Available from: http://whqlibdoc.who.int/ publications/2011/9789241564380-eng.pdf
2. World Health Organization. Joint TDR/EC expert consultation on biomarkers in tuberculosis-report of the joint TDR/EC expert consultation to evaluate the potential roles of biomarkers in the management of HIV-infected and HIV-uninfected patients with tuberculosis. Geneva, Switzerland, 2-3 July 2008 [accessed 2011 April 23]. Available from: http://www.who.int/tdr/publications/ documents/biomarkers.pdf
3. NewportMJ, Awomoyi AA, Blackwell JM. Polymorphism in the interferongamma receptor-1 gene and susceptibility to pulmonary tuberculosis in the Gambia. Scand J Immunol 2003;58:383-385.
4. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-354.
5. World Health Organization. Use of tuberculosis interferon-gamma release assay as (IGRAS) in low- and middle-income countries: policy statement. WHO/HTM/TB/201118. Geneva, Switzerland: World Health Organization; 2011.
6. Adetifa IM, Ota MO, Walther B, Hammond AS, Lugos MD, Jeffries DJ, Donkor SA, Adegbola RA, Hill PC. Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases. PLoS ONE 2010;5:e12502.
7. Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah D, Lugos MD, Donkor SA, Adegbola RA, Brookes RH. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006;6:66.
8. Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, Lugos MD, Adetifa IM, Donkor SA, Aiken AM, Howie SR, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 2008;3:e1379.
9. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 2007;175:282-287.
10. Lee SH, LewWJ, Kim HJ, Lee HK, Lee YM, Cho CH, Lee EJ, Lee DY, Ryu SW, Oh SY, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir Med 2010; 104:448-453.
11. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174: 831-839.
12. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007;4:e192.
13. Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, Sillah J, Lienhardt C, Corrah T, Manneh K, Drobniewski F, et al. Surveillance of drugresistant Mycobacterium tuberculosis in the Gambia. Int J Tuberc Lung Dis 2003;7:390-393.
14. Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola RA, Hill PC. Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in the Gambia. BMC Infect Dis 2007;7:122.
15. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD81 memory T cells. J Exp Med 1997;186:859-865.
16. Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, Adegbola RA, Brookes RH. Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in the Gambia. Int J Tuberc Lung Dis 2006;10:192-198.
17. Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, Chaisson RE, Golub JE. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med 2010;104:754-757.
18. Patin E, Harmant C, Kidd KK, Kidd J, Froment A,Mehdi SQ, Sica L, Heyer E, Quintana-Murci L. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 2006;27:720.
19. Jeffries DJ, Donkor S, Brookes RH, Fox A, Hill PC. Design and implementation of relational databases relevant to the diverse needs of a tuberculosis case contact study in the Gambia. Int J Tuberc Lung Dis 2004;8:1095-1099.
20. Walzl G, Ronacher K, HanekomW, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011;11:343-354.
21. Nicol MP, Pienaar D, Wood K, Eley B, Wilkinson RJ, Henderson H, Smith L, Samodien S, Beatty D. Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. Clin Infect Dis 2005;40:1301-1308.
22. Chee CB, KhinMar KW, Gan SH, Barkham TM, Koh CK, Shen L, Wang YT. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010;36:355-361.
23. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, Marocco R, Del Borgo C, Soscia F, Vullo V, et al. In vivo and in vitro effects of antituberculosis treatment on Mycobacterial interferongamma T cell response. PLoS ONE 2009;4:e5187.
24. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, Wilkinson RJ. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 2006;193:354-359.
25. Theron G, Peter J, Lenders L, van Zyl-Smit R, Meldau R, Govender U, Dheda K. Correlation of Mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting. PLoS ONE 2012;7:e37436.
26. Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, Shimao T. Waning of the specific interferon-gamma response after years of tuberculosis infection. Int J Tuberc Lung Dis 2007;11:1021-1025.
27. Barry CE III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845-855.
28. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193.
29. Kaech SM, Ahmed R. Memory CD81 T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-422.
30. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
31. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant AD. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int J Tuberc Lung Dis 2007;11:1232-1236.
32. World Health Organization. Gambia: tuberculosis profile [accessed 2011 December 3]. Available from: https://extranet.who.int/sree/Reports?op= Replet&name=/WHO-HQ-Reports/G2/PROD/EXT/TBCountryProfile&ISO2= gM&outtype=pdf
33. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009;4: e8517.
34. Adetifa IM, Ota MO, Jeffries DJ, Hammond A, Lugos MD, Donkor S, Patrick O, Adegbola RA, Hill PC. Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis J 2010;29:439-443.
35. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, Lugos MD, Donkor SA, Marshall RJ, Howie SR, Corrah T, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 2006;117: 1542-1548.
36. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children [accessed 2011 December 3]. Available from: whqlibdoc.who.int/hq/2006/ WHO-HTM-TB-2006.371-eng.pdf
37. Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest 2012;142:761-773.
38. Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, Churchyard GJ. Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials 2011;32:382-392.
39. Hill PC, Ota MO. Tuberculosis case-contact research in endemic tropical settings: design, conduct, and relevance to other infectious diseases. Lancet Infect Dis 2010;10:723-732.
40. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001;22: 485-502.